Cargando…
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
OBJECTIVE: To characterize unusual responses to PCSK9 inhibitor (PCSK9i) therapy in a real-world setting, given their extremely low prevalence in clinical trials. METHODS: A retrospective study of patients seen in a structured academic PCSK9i clinic who had LDL-C measurements before and after initia...
Autores principales: | Warden, Bruce A., Miles, Joshua R., Oleaga, Carlota, Ganda, Om P., Duell, P. Barton, Purnell, Jonathan Q., Shapiro, Michael D., Fazio, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315390/ https://www.ncbi.nlm.nih.gov/pubmed/34327453 http://dx.doi.org/10.1016/j.ajpc.2020.100012 |
Ejemplares similares
Ejemplares similares
-
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
por: Oleaga, Carlota, et al.
Publicado: (2021) -
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020) -
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020) -
Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice
por: Warden, Bruce A., et al.
Publicado: (2021) -
PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)